DOR Sigma Tau Letter Europe
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): February
21, 2007
Commission
File No. 000-16929
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1101
Brickell Ave., Suite 701 S
Miami,
FL
|
|
33131
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(305)
534-3383
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
|
Item
1.01
|
Entry
into a Material Definitive
Agreement.
|
As
previously reported, DOR BioPharma, Inc. (the “Company”) entered into a
non-binding letter of intent (the “Letter of Intent”) with Sigma-Tau
Pharmaceuticals, Inc. (“Sigma-Tau”), which granted Sigma-Tau an exclusive right
to negotiate terms and conditions for a possible business transaction or
strategic alliance regarding the Company’s lead product, orBec® (“oral
beclomethasone dipropionate”) and potentially other Company pipeline compounds
until March 1, 2007. As of February 21, 2007, Sigma-Tau has relinquished its
exclusive rights under the Letter of Intent with regard to acquisition
discussions. However, all other terms of the Letter of Intent remain in effect,
and the Company and Sigma-Tau are engaged in discussions for a European
collaboration relating to orBec®.
A
copy of
the Letter from Sigma-Tau is entered as Exhibit 10.1 to this Current Report
on
Form 8-K.
Item
9.01 Financial
Statements and Exhibits
(c)
Exhibits:
10.1 Letter
from Sigma Tau dated February 21, 2007
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA, INC.
By:
/s/
Christopher J. Schaber
Name:
Christopher J. Schaber
Title:
Chief Executive Officer
Date:
February 21, 2007
EXHIBIT
INDEX
Exhibit
No. Description
|
10.1
|
Letter
of Intent dated January 3, 2007 by and between DOR BioPharma, Inc.
and
Sigma-Tau Pharmaceuticals,
Inc.
|